Resistance to ALK inhibitors: Pharmacokinetics, mutations or bypass signaling?
Sign Up to like & getrecommendations! Published in 2017 at "Cell Cycle"
DOI: 10.1080/15384101.2016.1247568
Abstract: The approval of multitargeted anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) has been a success story for the management of advanced non-small-cell lung cancers (NSCLCs) over the last half a decade, with the 1st… read more here.
Keywords: alk inhibitors; resistance alk; alk; kinase ... See more keywords